|
|
Home | Search | Advance Search | Browse | Online Submission | Documentation & FAQ | Team | Contact us |
|
PolysacDB ID | 1001 |
Carbohydrate Name | Glucurunoxylomannan (Drugpedia) |
Carbohydrate Class | Capsular polysaccharide |
Microbe | Cryptococcus neoformans serotype A (NCBI Taxonomy) (Drugpedia) |
Basic Structure | A linear (1-->3)-linked mannan backbone singly substituted with nonreducing β(1-->2) xylose and β(1-->2) glucuronic acid side branches ; O-acetyl groups are present at C-6 of the mannosyl residues |
BCSDB Structure | 116826 |
Proposed functions | Antiphagocytic ; an important virulence factor |
Antigenic Nature used to produce antibodies | Glycoconjugates. |
Carrier Name | Pseudomonas aeruginosa exoprotein A (rEPA), tetanus toxoid |
Conjugation Method | GXM was derivatized by the following two methods. (i) In method 1, ADH [adipic acid dihydrazide] was introduced into GXM by the activation of carboxyl groups with EDAC. GXM (5 mg/ml of 0.2 M NaCl) was derivatized with 0.5 M ADH and 0.1 M EDAC at pH 4.85 for 3.5 h at room temperature, using a pH Stat. After extensive dialysis against 0.2 M NaCl, the reaction mixture was passed through a 2B-CL Sepharose column (1.5 by 30 cm) equilibrated in 0.2 M NaCl. The fractions containing GXM were pooled and concentrated to the original volume. (ii) In method 2, ADH was introduced into GXM by the activation of hydroxyl groups with CNBr. GXM (5 mg/ml of 0.2 M NaCl) was activated with an equal weight of CNBr at pH 10.5 for 6 min at 4°C, using a pH Stat. An equal volume of 0.5 M NaHCO3 (pH 8.5) containing 0.5 M ADH was added. The reaction mixture was tumbled at 3 to 8°C for 18 to 20 h, dialyzed against 0.2 M NaCl, and passed through a 2B-CL Sepharose column (1.5 by 30 cm). The fractions containing GXM were pooled and concentrated to the original volume. The reaction mixture, containing equal concentrations (3.0 to 7.5 mg/ml) of GXM-AH (derivatized by either method) and TT or rEPA in 0.2 M NaCl, was brought to pH 5.6 with 0.05 N HCl, and 0.05 to 0.1 M EDAC was added; the pH was maintained at 5.6 in a pH Stat for 1 to 3 h at 4°C. The reaction mixture was dialyzed against 0.2 M NaCl at 3 to 8°C and passed through a Sepharose 2B-CL column (1.5 by 30 cm) equilibrated in 0.2 M NaCl. The void volume fractions containing the GXM and the protein were pooled and stored in 0.01% thimerosal at 3 to 8°C |
Antibodies | Polysera |
Antibody type and class | IgM |
Assay System | Double immunodiffusion, ELISA |
Cross-reactivity | Polsera cross-reacted with capsular polysaccharides of C neoformans serotype A and D |
Proposed epitopes | O-acetyl groups, glucuronyl residues |
IEDB Epitope | 115576 |
Proposed Utility | The conjugate vaccines prepared through hydroxyl activation of glucurunoxylomannan are sufficiently immunogenic and appear to be suitable for clinical evaluation |
Curator ID | AA + AS |
Date of Curation | 01-01-2010 |
References | 1716613 |
PolysacDB ID | 1004 |
Carbohydrate Name | Capsular polysaccharide (Drugpedia) |
Carbohydrate Class | Capsular polysaccharide |
Microbe | Haemophilus influenzae type B (NCBI Taxonomy) (Drugpedia) |
Basic Structure | A relatively simple antigen consisting of repeating units of 3-β-D ribose-(1-->1)-D-ribitol-5-phosphate |
BCSDB Structure | 23423 |
Proposed functions | An important virulence determinant |
Antigenic Nature used to produce antibodies | Glycoconjugates |
Carrier Name | Neisseria meningitidis group B outer membrane protein complex (Hib PS-OMP) |
Conjugation Method | The strategy uses a oligopeptide spacer molecule whose parts are derived from both modified Haemophilus influenzae capsular polysaccharide and Neisseria meningitides group B outer membrane complex |
Antibodies | Polysera |
Antibody type and class | IgG1 and IgG2 |
Assay System | N\A |
Cross-reactivity | N/A |
Proposed epitopes | N\A |
IEDB Epitope | N/A |
Proposed Utility | These antibodies exert their protective effect by initiating complement-mediated activities including opsonization and bacterial lysis |
Curator ID | AA + AS |
Date of Curation | 01-01-2010 |
References | PMC296547 |
PolysacDB ID | 1005 |
Carbohydrate Name | Capsular polysaccharide (Drugpedia) |
Carbohydrate Class | Capsular polysaccharide |
Microbe | Haemophilus influenzae type B (NCBI Taxonomy) (Drugpedia) |
Basic Structure | A relatively simple antigen consisting of repeating units of 3-β-D ribose-(1-->1)-D-ribitol-5-phosphate |
BCSDB Structure | 23423 |
Proposed functions | An important virulence determinant |
Antigenic Nature used to produce antibodies | Glycoconjugates |
Carrier Name | Tetanus toxoid |
Conjugation Method | Protein solutions (25 mg/ml) and Adipic acid dihydrazide [ADH] (3.45 rag/rag protein) were reacted with three different concentrations of EDAC (0 1, 0.3, and 0.6 rag/rag protein) The pH of the reaction mixture was maintained at 4.7 ± 0.2 with 0.1 N HC! The reaction proceeded at room temperature for 3 h and the reaction mixtures were dialyzed at 3-8°C with two changes/d against 6 liter of 0 2 M NaCI. The albumin and polysaccharide derivatives were then dialyzed against two 6-liter changes of deionized water and freeze-dried. The polysaccharide was activated with CNBr. Briefly, a solution of polysaccharide (5.0 mg/ml), equilibrated at 4°C, was rapidly brought to pH 10.5 with 0.1 N NaOH. 100 mg/ml CNBr was added to a final concentration of 0.4 mg/mg polysaccharide, and the pH maintained at 10.5 for 6 rain. Then the reaction mixture was brought to pH 8 5 with 0.5 M NaHCO3, and the CNBr-actlvated polysaccharide added to an equal weight of ADH-protein. The reaction mixture was tumbled gently overnight at 3-8°C and then centrifuged at 16,000 g, 4°C for 20 ram. The supernatant was passed through a CL-4B Sepharose column, 1 5 × 90 cm, that was equihbrated with 0 2 M ammonium acetate. The void-volume fractions were pooled, dialyzed against 0.01 M phosphate-buffered 0.145 M NaCI, pH 7.0, at 3-8°C, and passed through a 045-nm membrane and stored at 3-8°C |
Antibodies | Polysera |
Antibody type and class | IgG and IgA |
Assay System | Radioimmunoassay |
Cross-reactivity | N/A |
Proposed epitopes | N\A |
IEDB Epitope | N/A |
Proposed Utility | These antibodies exert their protective effect by initiating complement-mediated activities including opsonization and bacterial lysis |
Curator ID | AA + AS |
Date of Curation | 02-01-2010 |
References | PMC2185954 |
PolysacDB ID | 1012 |
Carbohydrate Name | Capsular polysaccharide (Drugpedia) |
Carbohydrate Class | Capsular polysaccharide |
Microbe | Streptococcus Group B (NCBI Taxonomy) (Drugpedia) |
Basic Structure | A basic backbone of the following residues: -3-β-D-Galp-(1-->4) -β-D-Glcp[branched to 1-->4-D-Glp-α-D-NeuNACp]-(1-->6)-β-D-GlcNAcp-1- |
BCSDB Structure | 6237 |
Proposed functions | Invades the blood stream and multiply. This property of invasiveness is related to the anti-phagocytic properties conferred by its Capsular polysaccharide |
Antigenic Nature used to produce antibodies | Glycoconjugates |
Carrier Name | Tetanus toxoid |
Conjugation Method | Type III polysaccharide was activated with cyanogen bromide at pH 10.5 for 6 min at 4°C in a pH stat. Adipic acid dihydrazide [AH] was added in 0.5 M NaHCO3 to a final concentration of 0.25 M, pH 8.5. After tumbling for 18 h at 3 to 8°C, the reaction mixture was dialyzed against 0.2 M NaCl at 3 to 8°C and passed through a 4B-CL Sepharose column. The polysaccharide-containing fractions were pooled, dialyzed against sterile pyrogen-free water, and freeze-dried. A solution containing 10 mg each of type III-AH and tetanus toxoid [TT} per ml was brought to pH 5.6 with 0.1 N HCl. 1-Ethyl-3-(3-dimethylaminopropyl)-carbodiimide was added to a final concentration of 0.05 M, and the pH was maintained at 5.6 with 0.1 N NaOH for 3 h at room temperature. The reaction mixture was dialyzed against 0.2 M NaCl at 3 to 8°C and was passed through a 4B-CL Sepharose column (5 by 95 cm) equilibrated in 0.2 M NaCl. The void volume fractions were stored in 0.01% thimerosal at 3 to 8°C |
Antibodies | Polysera |
Antibody type and class | Mainly IgG, particularly IgG1 and IgG3 |
Assay System | Double immunodiffusion, capillary precipitation, ELISA |
Cross-reactivity | N/A |
Proposed epitopes | N\A |
IEDB Epitope | N/A |
Proposed Utility | Antibodies elicited by the conjugates had in vitroopsonic activities proposed to be a correlate of protective immunity |
Curator ID | AA + AS |
Date of Curation | 04-01-2010 |
References | PMC258520 |
PolysacDB ID | 1015 |
Carbohydrate Name | Beta-glucan (Drugpedia) |
Carbohydrate Class | Capsular polysaccharide |
Microbe | Candida albicans (NCBI Taxonomy) (Drugpedia) |
Basic Structure | Glucans are a heterogeneous group of glucose polymers, consisting of a backbone of β(1-->3)-linked β-D-glucopyranosyl units with β(1-->6)-linked side chains of varying distribution and length |
BCSDB Structure | 125281 |
Proposed functions | Glucan is an essential cell wall component in pathogenic fungi and plays a critical role in cell viability |
Antigenic Nature used to produce antibodies | Glycoconjugates |
Carrier Name | Diphtheria toxoid CRM 197 |
Conjugation Method | A 20-fold molar excess of activated polysaccharide was reacted overnight with the protein, at room temperature, in 10 mM phosphate buffer, pH 7.2. The unbound polysaccharide was separated from the glyco-conjugate by ultrafiltration, using Amicon 10-kD filter devices |
Antibodies | Polysera |
Antibody type and class | IgG |
Assay System | Invivo protection assays, growth inhibition assays, indirect ELISA |
Cross-reactivity | N/A |
Proposed epitopes | N\A |
IEDB Epitope | 76671 |
Proposed Utility | The Lam-CRM conjugate is immunogenic and protective against systemic candidiasis in mice. The antibodies induce passive protection in mice against systemic and mucosal candidiasis |
Curator ID | AA + AS |
Date of Curation | 04-01-2010 |
References | PMC2212864 |
PolysacDB ID | 1046 |
Carbohydrate Name | Lipopolysaccharide (Drugpedia) |
Carbohydrate Class | Lipopolysaccharide |
Microbe | Salmonella typhimurium SR-11 (NCBI Taxonomy) (Drugpedia) |
Basic Structure | LPS is composed of three parts: (1) lipid A, (2) core polysaccharide, and (3) O antigen. The lipid A region contains two glucosamine sugar derivatives, each with three fatty acids and phosphate or pyrophosphate attached. The core polysaccharide has KDO and attached to lipid A. The side chain O is small polysaccharide chain extending outward from the core, it has several peculiar sugars and varies in composition between bacterial strains. |
BCSDB Structure | N/A |
Proposed functions | LPS is most unusual constituents of outer membrane. It plays important role in host defence avoidance. LPS contributes to the negative charge of the bacterial surface. Lipid A is often toxic and act as endotoxin |
Antigenic Nature used to produce antibodies | Live S.typhimurium SR cells. |
Carrier Name | Nil |
Conjugation Method | Nil |
Antibodies | Polysera |
Antibody type and class | IgG |
Assay System | ELISA Hemaggluttination assay |
Cross-reactivity | This antibody was cross-reactive with Salmonella typhimurium LT-2, Salmonella typhimurium derby. Salmonella typhimurium dublin, Salmonella enteritidis and Salmonella paratyphi A. |
Proposed epitopes | O-polysaccharide |
IEDB Epitope | N/A |
Proposed Utility | This antibody can be used in serological assays to detect the desired antigen. |
Curator ID | AA + AS |
Date of Curation | 14-01-2010 |
References | 6203984 |
PolysacDB ID | 1122 |
Carbohydrate Name | O-polysaccharide (Drugpedia) |
Carbohydrate Class | Lipopolysaccharide |
Microbe | Actinobacillus pleuropneumoniae serotype 1 (NCBI Taxonomy) (Drugpedia) |
Basic Structure | The O-polsaccharide structure is as follows : --6)-α-D-Glcp-(1-->2)-α-L-Rhap-(l-->2)-α-L-Rhap-(1--. which is linked to 1-D-GlcpNAc chains on its rhamnopyranosyl residue via 1-->3 linkage. |
BCSDB Structure | N/A |
Proposed functions | LPS is an important virulence factor. It molecule plays an important role in adherence of the bacterium to porcine respiratory tract cells and mucus |
Antigenic Nature used to produce antibodies | Formalin-fixed A. pleuropneumoniae serotype 1 cells |
Carrier Name | Nil |
Conjugation Method | Nil |
Antibodies | Polysera |
Antibody type and class | N/A |
Assay System | ELISA |
Cross-reactivity | This antibody cross-reacted with serotypes 9 and 11 |
Proposed epitopes | The epitope was deduced to contain the terminal nonreducing -D-Glc NAc residues |
IEDB Epitope | N/A |
Proposed Utility | This antisera not only helped in serotyping analysis but also helped in deducing the epitopes recognized |
Curator ID | AA + AS |
Date of Curation | 06-02-2010 |
References | PMC206369 |
PolysacDB ID | 1123 |
Carbohydrate Name | O-polysaccharide (Drugpedia) |
Carbohydrate Class | Lipopolysaccharide |
Microbe | Actinobacillus pleuropneumoniae serotype 9 (NCBI Taxonomy) (Drugpedia) |
Basic Structure | The structure consists of trisaccharide backbone randomly substituted by N-acetyl-β-D-glucosamine end groups (to the extent of 25%) |
BCSDB Structure | 131785 |
Proposed functions | LPS is an important virulence factor. It molecule plays an important role in adherence of the bacterium to porcine respiratory tract cells and mucus |
Antigenic Nature used to produce antibodies | Formalin-fixed A. pleuropneumoniae serotype 9 cells |
Carrier Name | Nil |
Conjugation Method | Nil |
Antibodies | Polysera |
Antibody type and class | N/A |
Assay System | ELISA |
Cross-reactivity | This antibody cross-reacted with serotypes 1 and 12. also cross-reacted with deaminated Serotype1 O-PS |
Proposed epitopes | The epitope was deduced to contain the terminal nonreducing -D-Glc NAc residues. A second epitope was said to be directed to linear regions of the backbone polymer |
IEDB Epitope | N/A |
Proposed Utility | This antisera not only helped in serotyping analysis but also helped in deducing the epitopes recognized |
Curator ID | AA + AS |
Date of Curation | 06-02-2010 |
References | PMC206369 |
PolysacDB ID | 1124 |
Carbohydrate Name | Capsular polysaccharide (Drugpedia) |
Carbohydrate Class | Capsular polysaccharide |
Microbe | Actinobacillus pleuropneumoniae serotype 1 (NCBI Taxonomy) (Drugpedia) |
Basic Structure | N/A |
BCSDB Structure | N/A |
Proposed functions | N/A |
Antigenic Nature used to produce antibodies | Whole cells |
Carrier Name | Nil |
Conjugation Method | Nil |
Antibodies | Polysera |
Antibody type and class | N/A |
Assay System | ELISA |
Cross-reactivity | This antibody was specific to serotype 1 only |
Proposed epitopes | N/A |
IEDB Epitope | N/A |
Proposed Utility | N/A |
Curator ID | AA + AS |
Date of Curation | 07-02-2010 |
References | PMC206369 |
PolysacDB ID | 1149 |
Carbohydrate Name | Lipopolysaccharide (Drugpedia) |
Carbohydrate Class | Lipopolysaccharide |
Microbe | Bacteroides fragilis NCTC 9344 (NCBI Taxonomy) (Drugpedia) |
Basic Structure | N/A |
BCSDB Structure | N/A |
Proposed functions | LPS polysaccharide of B. fragilis may represent a virulence factor |
Antigenic Nature used to produce antibodies | Live cells of B. fragilis strains NCTC 9344 |
Carrier Name | Nil |
Conjugation Method | Nil |
Antibodies | Polysera |
Antibody type and class | N/A |
Assay System | Immunoblotting |
Cross-reactivity | N/A |
Proposed epitopes | N/A |
IEDB Epitope | N/A |
Proposed Utility | N/A |
Curator ID | AA + AS |
Date of Curation | 17-02-2010 |
References | 2432160 |
PolysacDB ID | 1150 |
Carbohydrate Name | Lipopolysaccharide (Drugpedia) |
Carbohydrate Class | Lipopolysaccharide |
Microbe | Bacteroides fragilis strains GNAB4 (NCBI Taxonomy) (Drugpedia) |
Basic Structure | N/A |
BCSDB Structure | N/A |
Proposed functions | LPS polysaccharide of B. fragilis may represent a virulence factor |
Antigenic Nature used to produce antibodies | Live cells of B. fragilis strains GNAB4 |
Carrier Name | Nil |
Conjugation Method | Nil |
Antibodies | Polysera |
Antibody type and class | N/A |
Assay System | Immunoblotting |
Cross-reactivity | N/A |
Proposed epitopes | N/A |
IEDB Epitope | N/A |
Proposed Utility | N/A |
Curator ID | AA + AS |
Date of Curation | 17-02-2010 |
References | 2432160 |
PolysacDB ID | 1151 |
Carbohydrate Name | Lipopolysaccharide (Drugpedia) |
Carbohydrate Class | Lipopolysaccharide |
Microbe | Bacteroides fragilis strains GNAB92 (NCBI Taxonomy) (Drugpedia) |
Basic Structure | N/A |
BCSDB Structure | N/A |
Proposed functions | LPS polysaccharide of B. fragilis may represent a virulence factor |
Antigenic Nature used to produce antibodies | Live cells of B. fragilis strains GNAB 92 |
Carrier Name | Nil |
Conjugation Method | Nil |
Antibodies | Polysera |
Antibody type and class | N/A |
Assay System | Immunoblotting |
Cross-reactivity | N/A |
Proposed epitopes | N/A |
IEDB Epitope | N/A |
Proposed Utility | N/A |
Curator ID | AA + AS |
Date of Curation | 18-02-2010 |
References | 2432160 |
PolysacDB ID | 1155 |
Carbohydrate Name | Lipopolysaccharide (Drugpedia) |
Carbohydrate Class | Lipopolysaccharide |
Microbe | Bacteroides fragilis NCTC 9343 (NCBI Taxonomy) (Drugpedia) |
Basic Structure | The polysaccharide part of the LPS mainly consists of two fractions : PSI : β-D-Galp(1-->6)β-D-Galp(1-->6)β-D-Galp(1-->6)Residue1-α-D-Glcp [branched to Residue no. 2](1-->2)α-L-Rhap and PSII : β-D-Galp(1-->4)α-D-Glcp [Branched to β-D-Galp(1-->6)](1-->2)α-L-Rhap |
BCSDB Structure | N/A |
Proposed functions | LPS polysaccharide of B. fragilis may represent a virulence factor |
Antigenic Nature used to produce antibodies | Whole cells of B. fragilis NCTC 9343 |
Carrier Name | Nil |
Conjugation Method | Nil |
Antibodies | Polysera |
Antibody type and class | N/A |
Assay System | ELISA |
Cross-reactivity | This antisera cross-reacted with 13 strains of B. fragilis |
Proposed epitopes | Galactose chains was proposed to be an important part of the epitope |
IEDB Epitope | N/A |
Proposed Utility | This antisera can be used in serotyping schemes for this particular bacteria |
Curator ID | AA + AS |
Date of Curation | 19-02-2010 |
References | PMC262078 |
PolysacDB ID | 1156 |
Carbohydrate Name | Lipopolysaccharide (Drugpedia) |
Carbohydrate Class | Lipopolysaccharide |
Microbe | Bacteroides fragilis ATCC 23745 (NCBI Taxonomy) (Drugpedia) |
Basic Structure | N/A |
BCSDB Structure | N/A |
Proposed functions | LPS polysaccharide of B. fragilis may represent a virulence factor |
Antigenic Nature used to produce antibodies | Whole cells of B. fragilis NCTC 9344 |
Carrier Name | Nil |
Conjugation Method | Nil |
Antibodies | Polysera |
Antibody type and class | N/A |
Assay System | ELISA |
Cross-reactivity | This antisera cross-reacted with 13 strains of B. fragilis |
Proposed epitopes | Galactose chains was proposed to be an important part of the epitope |
IEDB Epitope | N/A |
Proposed Utility | This antisera can be used in serotyping schemes for this particular bacteria |
Curator ID | AA + AS |
Date of Curation | 20-02-2010 |
References | PMC262078 |
PolysacDB ID | 1157 |
Carbohydrate Name | Capsular Polysaccharide (Drugpedia) |
Carbohydrate Class | Capsular polysaccharide |
Microbe | Bacteroides fragilis strain 638R (NCBI Taxonomy) (Drugpedia) |
Basic Structure | N/A |
BCSDB Structure | N/A |
Proposed functions | Capsular polysaccharide of B. fragilis may represent a virulence factor |
Antigenic Nature used to produce antibodies | Whole cells of B. fragilis strain 638R |
Carrier Name | Nil |
Conjugation Method | Nil |
Antibodies | Polysera |
Antibody type and class | N/A |
Assay System | Immunodiffusion |
Cross-reactivity | N/A |
Proposed epitopes | N/A |
IEDB Epitope | N/A |
Proposed Utility | This antisera helped in the discovery of 3 different types of surface polysaccharides on the capsule |
Curator ID | AA + AS |
Date of Curation | 21-02-2010 |
References | PMC98163 |
PolysacDB ID | 1262 |
Carbohydrate Name | O-polysaccharide (Drugpedia) |
Carbohydrate Class | Lipopolysaccharide |
Microbe | Campylobacter fetus 553 and 554 (NCBI Taxonomy) (Drugpedia) |
Basic Structure | The LPS molecule of C. fetus is composed of three distinct structural domains: a hydrophobic lipid A portion which forms the outer leaflet of the outer membrane and which contains the endotoxic activity, a low-molecular-weight oligosaccharide core complex, and a variable-length O-specific polysaccharide chain with repeating oligosaccharide units (O-antigen) |
BCSDB Structure | N/A |
Proposed functions | The LPS O-antigens are the basis of the C. fetus heat-stable serotyping Scheme |
Antigenic Nature used to produce antibodies | A mixture (1:1) of C. fetus 553 and 554 formalin-killed cells |
Carrier Name | Nil |
Conjugation Method | Nil |
Antibodies | Polysera |
Antibody type and class | N/A |
Assay System | Indirect ELISA, immunoblotting, |
Cross-reactivity | This antibody was specific to O antigen of C. fetus 553 and 554 |
Proposed epitopes | N/A |
IEDB Epitope | N/A |
Proposed Utility | This antisera can be used to serotype C. fetus strains |
Curator ID | AA + AS |
Date of Curation | 02-05-2010 |
References | PMC98852 |
PolysacDB ID | 1448 |
Carbohydrate Name | Capsular polysaccharide [heteroglycan] (Drugpedia) |
Carbohydrate Class | Capsular polysaccharide |
Microbe | Enterococcus faecalis type V (NCBI Taxonomy) (Drugpedia) |
Basic Structure | It is composed of rhamnose, glucose, galactose, mannosamine, and glucosamine |
BCSDB Structure | N/A |
Proposed functions | These polysaccharides are major virulence factors |
Antigenic Nature used to produce antibodies | Glycoconjugates |
Carrier Name | Tetanus toxoid |
Conjugation Method | PSs were oxidized with 0.5 ml of 10 mM NaI4 at room temperature for 90 min, dialyzed and lyophilized. The oxidized PS was reacted with 2 mg of tetanus toxoid in PBS with the addition of 10 mg of NaCNBH3 |
Antibodies | Polysera |
Antibody type and class | N/A |
Assay System | Competitive inhibition ELISA |
Cross-reactivity | This antibody cross-reacted with E. faecalis strain 68114, 324057B and R19001. did not cross-react with E. faecalis type II PS and vancomycin-resistant E. faecium B210860 |
Proposed epitopes | N/A |
IEDB Epitope | N/A |
Proposed Utility | N/A |
Curator ID | AA + AS |
Date of Curation | 13-07-2010 |
References | PMC1538600 |
PolysacDB ID | 1449 |
Carbohydrate Name | Capsular polysaccharide [heteroglycan] (Drugpedia) |
Carbohydrate Class | Capsular polysaccharide |
Microbe | Enterococci faecium B210860 (NCBI Taxonomy) (Drugpedia) |
Basic Structure | It is composed of rhamnose, glucose, galactose, mannosamine, and glucosamine |
BCSDB Structure | N/A |
Proposed functions | These polysaccharides are major virulence factors |
Antigenic Nature used to produce antibodies | Glycoconjugates |
Carrier Name | Tetanus toxoid |
Conjugation Method | PSs were oxidized with 0.5 ml of 10 mM NaI4 at room temperature for 90 min, dialyzed and lyophilized. The oxidized PS was reacted with 2 mg of tetanus toxoid in PBS with the addition of 10 mg of NaCNBH4 |
Antibodies | Polysera |
Antibody type and class | N/A |
Assay System | Competitive inhibition ELISA |
Cross-reactivity | This antibody was specific to E. faecium B210860 only and did not cross-react with polysaccharides from E. faecalis type II, 68114, and R19001 |
Proposed epitopes | N/A |
IEDB Epitope | N/A |
Proposed Utility | N/A |
Curator ID | AA + AS |
Date of Curation | 13-07-2010 |
References | PMC1538600 |
PolysacDB ID | 1460 |
Carbohydrate Name | Lipopolysaccharide (Drugpedia) |
Carbohydrate Class | Lipopolysaccharide |
Microbe | Haemophilus ducreyi CCUG 4438 (NCBI Taxonomy) (Drugpedia) |
Basic Structure | It consist of an oligosaccharide core ketosidically linked via a 3-deoxy-D-manno-octulosonic acid (Kdo) residue to the lipid A region. The oligosaccharide core characteristic of these bacteria has been divided into two regions: (i) an inner core, consisting of three L-glycero-D-manno-heptose (Hep) residues and one phosphorylated Kdo residue, and (ii) an outer core, with one or more heterogeneous oligosaccharide branches containing mainly galactose (Gal) and glucose (Glc) residues |
BCSDB Structure | N/A |
Proposed functions | LPS plays an important role in the infection process |
Antigenic Nature used to produce antibodies | Whole cells |
Carrier Name | Nil |
Conjugation Method | Nil |
Antibodies | Polysera |
Antibody type and class | N/A |
Assay System | ELISA and immunoblotting |
Cross-reactivity | The antiserum to CCUG 4438 reacted with only its homologous strain and strain ITM 4747 |
Proposed epitopes | N/A |
IEDB Epitope | N/A |
Proposed Utility | This antisera would aid in the classification of H. ducreyi for epidemiological purposes |
Curator ID | AA + AS |
Date of Curation | 23-07-2010 |
References | PMC175445 |
PolysacDB ID | 1461 |
Carbohydrate Name | Lipopolysaccharide (Drugpedia) |
Carbohydrate Class | Lipopolysaccharide |
Microbe | Haemophilus ducreyi CCUG 7470 (NCBI Taxonomy) (Drugpedia) |
Basic Structure | It consist of an oligosaccharide core ketosidically linked via a 3-deoxy-D-manno-octulosonic acid (Kdo) residue to the lipid A region. The oligosaccharide core characteristic of these bacteria has been divided into two regions: (i) an inner core, consisting of three L-glycero-D-manno-heptose (Hep) residues and one phosphorylated Kdo residue, and (ii) an outer core, with one or more heterogeneous oligosaccharide branches containing mainly galactose (Gal) and glucose (Glc) residues |
BCSDB Structure | N/A |
Proposed functions | LPS plays an important role in the infection process |
Antigenic Nature used to produce antibodies | Whole cells |
Carrier Name | Nil |
Conjugation Method | Nil |
Antibodies | Polysera |
Antibody type and class | N/A |
Assay System | ELISA and immunoblotting |
Cross-reactivity | The antiserum to CCUG 7470 reacted with all H. ducreyi strains |
Proposed epitopes | N/A |
IEDB Epitope | N/A |
Proposed Utility | This antisera would aid in the classification of H. ducreyi for epidemiological purposes |
Curator ID | AA + AS |
Date of Curation | 23-07-2010 |
References | PMC175445 |
PolysacDB ID | 1464 |
Carbohydrate Name | Capsular polysaccharide (Drugpedia) |
Carbohydrate Class | Capsular polysaccharide |
Microbe | Enterococcus faecalis 12030 (NCBI Taxonomy) (Drugpedia) |
Basic Structure | Glycerol teichoic acid-like molecules with a carbohydrate backbone structure of 6-α-D-glucose- 1-->2 glycerol-3-PO4 with substitution on carbon 2 of the glucose with an α-2-1-D-glucose residue |
BCSDB Structure | 2446 |
Proposed functions | These polysaccharides are major virulence factors |
Antigenic Nature used to produce antibodies | Gentamicin-killed Enterococcus faecalis strains |
Carrier Name | Nil |
Conjugation Method | Nil |
Antibodies | Polysera |
Antibody type and class | N/A |
Assay System | Opsonophagocytic assay, immunoelectron microscopy |
Cross-reactivity | This antisera reacted with the homologous strain (12030) and mediated opsonic killing of 33% of all strains tested. In addition, this serum killed two (28%) of seven vancomycin-resistant Enterococcus faecium strains |
Proposed epitopes | N/A |
IEDB Epitope | N/A |
Proposed Utility | This antisera was opsonophagcytic |
Curator ID | AA + AS |
Date of Curation | 24-07-2010 |
References | 10024563 |
PolysacDB ID | 1465 |
Carbohydrate Name | Capsular polysaccharide (Drugpedia) |
Carbohydrate Class | Capsular polysaccharide |
Microbe | Enterococcus faecalis 12030 (NCBI Taxonomy) (Drugpedia) |
Basic Structure | Glycerol teichoic acid-like molecules with a carbohydrate backbone structure of 6-α-D-glucose- 1-->2 glycerol-3-PO4 with substitution on carbon 2 of the glucose with an α-2-1-D-glucose residue |
BCSDB Structure | 2446 |
Proposed functions | These polysaccharides are major virulence factors |
Antigenic Nature used to produce antibodies | Capsular polysaccharide |
Carrier Name | Nil |
Conjugation Method | Nil |
Antibodies | Polysera |
Antibody type and class | IgM |
Assay System | ELISA and opsonophagocytic assay |
Cross-reactivity | The antisera cross-reacted with Enterococcus faecalis OG1RF and against two serologically related, vancomycin-resistant Enterococcus faecium clinical isolates |
Proposed epitopes | N/A |
IEDB Epitope | N/A |
Proposed Utility | These antibodies may be useful for prophylaxis and treatment of enterococcal infections |
Curator ID | AA + AS |
Date of Curation | 25-07-2010 |
References | 15184433 |
PolysacDB ID | 1470 |
Carbohydrate Name | Unknown carbohydrate (Drugpedia) |
Carbohydrate Class | Glycoprotein |
Microbe | Helicobacter pylori D273 (NCBI Taxonomy) (Drugpedia) |
Basic Structure | N/A |
BCSDB Structure | N/A |
Proposed functions | N/A |
Antigenic Nature used to produce antibodies | Whole cells |
Carrier Name | Nil |
Conjugation Method | Nil |
Antibodies | Polysera |
Antibody type and class | N/A |
Assay System | ELISA, Immunoelectron microscopy, immunofluorescence and immunoperoxidase assays |
Cross-reactivity | This antisera was specific to Helicobacter pylori and did not cross-react with other Helicobacter species (H. fennelliae and H.mustelae) did not react |
Proposed epitopes | N/A |
IEDB Epitope | N/A |
Proposed Utility | This antisera may yield useful information concerning the real surface of the bacterium |
Curator ID | AA + AS |
Date of Curation | 27-07-2010 |
References | PMC280910 |
PolysacDB ID | 1494 |
Carbohydrate Name | Capsular polysaccharide (Drugpedia) |
Carbohydrate Class | Capsular polysaccharide |
Microbe | Cryptococcus neoformans Serotype A [strain 24064] (NCBI Taxonomy) (Drugpedia) |
Basic Structure | The major component of C. neoformans capsular polysaccharide is glucurunoxylomannan [GXM] consisting of an unbranched mannose backbone substituted with xylose, glucuronic acid and O-acetyl residues |
BCSDB Structure | N/A |
Proposed functions | C. neoformans has a large polysaccharide capsule that is a determinant of virulence. The capsular polysaccharide causes immunologic paralysis and inhibits phagocytosis by macrophages. Soluble C. neoformans capsular polysaccharide enhances human immunodeficiency virus [HIV] infection in cultured cells, suggesting a new pathogenic role in AIDS |
Antigenic Nature used to produce antibodies | Whole cells |
Carrier Name | Nil |
Conjugation Method | Nil |
Antibodies | Polysera |
Antibody type and class | IgG [predominantly IgG1] |
Assay System | ELISA |
Cross-reactivity | This antibody cross-reacted with Serotype D strains |
Proposed epitopes | N/A |
IEDB Epitope | N/A |
Proposed Utility | N/A |
Curator ID | AA + AS |
Date of Curation | 03-08-2010 |
References | 1583327 |
PolysacDB ID | 1495 |
Carbohydrate Name | Capsular polysaccharide (Drugpedia) |
Carbohydrate Class | Capsular polysaccharide |
Microbe | Cryptococcus neoformans Serotype A [strain 24064] (NCBI Taxonomy) (Drugpedia) |
Basic Structure | The major component of C. neoformans capsular polysaccharide is glucurunoxylomannan [GXM] consisting of an unbranched mannose backbone substituted with xylose, glucuronic acid and O-acetyl residues |
BCSDB Structure | N/A |
Proposed functions | C. neoformans has a large polysaccharide capsule that is a determinant of virulence. The capsular polysaccharide causes immunologic paralysis and inhibits phagocytosis by macrophages. Soluble C. neoformans capsular polysaccharide enhances human immunodeficiency virus [HIV] infection in cultured cells, suggesting a new pathogenic role in AIDS |
Antigenic Nature used to produce antibodies | Whole cells |
Carrier Name | Nil |
Conjugation Method | Nil |
Antibodies | Polysera |
Antibody type and class | IgM |
Assay System | ELISA |
Cross-reactivity | This antibody cross-reacted with Serotype D strains |
Proposed epitopes | N/A |
IEDB Epitope | N/A |
Proposed Utility | N/A |
Curator ID | AA + AS |
Date of Curation | 03-08-2010 |
References | 1583327 |
PolysacDB ID | 1496 |
Carbohydrate Name | Glucurunoxylomannan (Drugpedia) |
Carbohydrate Class | Capsular polysaccharide |
Microbe | Cryptococcus neoformans Serotype A [strain 24064] (NCBI Taxonomy) (Drugpedia) |
Basic Structure | The major component of C. neoformans capsular polysaccharide is glucurunoxylomannan [GXM] consisting of an unbranched mannose backbone substituted with xylose, glucuronic acid and O-acetyl residues |
BCSDB Structure | N/A |
Proposed functions | C. neoformans has a large polysaccharide capsule that is a determinant of virulence. The capsular polysaccharide causes immunologic paralysis and inhibits phagocytosis by macrophages. Soluble C. neoformans capsular polysaccharide enhances human immunodeficiency virus [HIV] infection in cultured cells, suggesting a new pathogenic role in AIDS |
Antigenic Nature used to produce antibodies | Glycoconjugates |
Carrier Name | Tetanus toxoid |
Conjugation Method | GXM was conjugated to tetanus toxoid using CDAP precipitation |
Antibodies | Polysera |
Antibody type and class | IgG [predominantly IgG1] |
Assay System | ELISA |
Cross-reactivity | This antibody cross-reacted with Serotype D strains |
Proposed epitopes | N/A |
IEDB Epitope | N/A |
Proposed Utility | N/A |
Curator ID | AA + AS |
Date of Curation | 04-08-2010 |
References | 1583327 |
PolysacDB ID | 1503 |
Carbohydrate Name | O-polysaccharide (Drugpedia) |
Carbohydrate Class | Lipopolysaccharide |
Microbe | Acinetobacter baumannii strain 24 (NCBI Taxonomy) (Drugpedia) |
Basic Structure | Acinetobacter LPSs consist of a polysaccharide covalently linked to a lipid component, termed lipid A, which anchors the LPS in the outer membrane. This polysaccharide is divided into the core oligosaccharide (linked to lipid A) and the O-polysaccharide or O-antigen. This type of LPS is referred to as the smooth- or S-form phenotype; the O-antigens are characteristic for a given LPS and the parental bacterial strain |
BCSDB Structure | 5534 |
Proposed functions | Since all recently investigated LPSs from Acinetobacter strains have been shown to be of the smooth phenotype, a serotyping scheme for identification of members of this genus may also be possible |
Antigenic Nature used to produce antibodies | Heat killed bacteria |
Carrier Name | Nil |
Conjugation Method | Nil |
Antibodies | Polysera |
Antibody type and class | N/A |
Assay System | Enzyme immunoassay |
Cross-reactivity | The antisera cross-reacted with 13 strains A. baumannii |
Proposed epitopes | N/A |
IEDB Epitope | N/A |
Proposed Utility | This Mab can be used to detect the presence of bacterial antigens in lungs from infected animals |
Curator ID | AA + AS |
Date of Curation | 06-08-2010 |
References | PMC103717 |
PolysacDB ID | 1513 |
Carbohydrate Name | Lipopolysaccharide (Drugpedia) |
Carbohydrate Class | Lipopolysaccharide |
Microbe | Klebsiella strains KD2 (NCBI Taxonomy) (Drugpedia) |
Basic Structure | O-1 side chain of the LPS is proposed to contain a disaccharide repeat unit consisting of [-α-D-Galp-(1->3)-β-D-Galf-] (1->4), where Gal is galactose |
BCSDB Structure | N/A |
Proposed functions | These major cell surface antigens play important roles in the ability of the bacterium to evade host cell defenses |
Antigenic Nature used to produce antibodies | Formalinized whole cells |
Carrier Name | Nil |
Conjugation Method | Nil |
Antibodies | Polysera |
Antibody type and class | N/A |
Assay System | ELISA and immunoblotting |
Cross-reactivity | The antisera reacted most strongly against the HMW-LPS fraction of Kliebsiella strain KD2 but also recognized the LMW-LPS of KLebsiella strains KD37 and KD2 |
Proposed epitopes | N/A |
IEDB Epitope | N/A |
Proposed Utility | This antibody may help in the stuctural and functional elucidation of O1 side chain of Klebsiella LPS |
Curator ID | AA + AS |
Date of Curation | 09-08-2010 |
References | PMC259910 |
PolysacDB ID | 1514 |
Carbohydrate Name | Lipopolysaccharide (Drugpedia) |
Carbohydrate Class | Lipopolysaccharide |
Microbe | Klebsiella strains KD37 (NCBI Taxonomy) (Drugpedia) |
Basic Structure | O-1 side chain of the LPS is proposed to contain a disaccharide repeat unit consisting of [-α-D-Galp-(1->3)-β-D-Galf-] (1->4), where Gal is galactose |
BCSDB Structure | N/A |
Proposed functions | These major cell surface antigens play important roles in the ability of the bacterium to evade host cell defenses |
Antigenic Nature used to produce antibodies | Formalinized whole cells |
Carrier Name | Nil |
Conjugation Method | Nil |
Antibodies | Polysera |
Antibody type and class | N/A |
Assay System | ELISA and immunoblotting |
Cross-reactivity | This antisera reacted with the full complement of High molecular weight LPS and Low molecular weight LPS but had no apparent response against the lipid A core |
Proposed epitopes | N/A |
IEDB Epitope | N/A |
Proposed Utility | This antibody may help in the stuctural and functional elucidation of O1 side chain of Klebsiella LPS |
Curator ID | AA + AS |
Date of Curation | 09-08-2010 |
References | PMC259910 |
PolysacDB ID | 1540 |
Carbohydrate Name | Excreted Factor [EF] antigen (Drugpedia) |
Carbohydrate Class | Glycoprotein |
Microbe | Leishmania tropica major (NCBI Taxonomy) (Drugpedia) |
Basic Structure | N/A |
BCSDB Structure | N/A |
Proposed functions | N/A |
Antigenic Nature used to produce antibodies | Living promastigotes |
Carrier Name | Nil |
Conjugation Method | Nil |
Antibodies | Polysera |
Antibody type and class | IgG and IgM |
Assay System | Immunodiffusion |
Cross-reactivity | The antisera cross-reacted with Israeli and Russian L. tropica major, L. mexicana, Leishmania aethiopica, and Leishmania enriettii and L. tropica minor |
Proposed epitopes | N/A |
IEDB Epitope | N/A |
Proposed Utility | This antisera would help in the serotyping of Leishmania species |
Curator ID | AA + AS |
Date of Curation | 02-09-2010 |
References | PMC270766 |
PolysacDB ID | 1571 |
Carbohydrate Name | Lipopolysaccharide (Drugpedia) |
Carbohydrate Class | Lipopolysaccharide |
Microbe | Leptospira interrogans serovar pomona (NCBI Taxonomy) (Drugpedia) |
Basic Structure | The oligosaccharide contained rhamnose, ribose, glucose, and glucosamine |
BCSDB Structure | N/A |
Proposed functions | N/A |
Antigenic Nature used to produce antibodies | Glycoconjugates |
Carrier Name | Diphtheria toxoid |
Conjugation Method | The oligosaccharide was modified as follows : it was dissolved in N-ethylmorpholine-water-12 N HCl (2.5:6.5:1 [vol/vol/vol], pH 8.5) in concentrations of approximately 24 umol in 250ul. 125umol of N-succinimidyl S-acetylmercaptoacetate in 250ul of N,N dimethylacetamide was added to the oligosaccharide. This solution was added to modified diphtheria toxoid |
Antibodies | Polysera |
Antibody type and class | IgG and IgM |
Assay System | Enzyme Immunoassay, immunoblotting and dot blot |
Cross-reactivity | This antisera cross-reacted with LPS from some other leptospiral serovars (serovars hardjobovis, ballum, copenhageni, canicola, grippotyphosa, and batavia) and LPS from other bacteria (Salmonella typhimurium and the Re mutant of Shigella flexneri) and did not react with serovars australis, grippotyphosa, ballum, or tarassovi |
Proposed epitopes | N/A |
IEDB Epitope | N/A |
Proposed Utility | This antiserum induced a high CL response in mouse macrophage monolayers |
Curator ID | AA + AS |
Date of Curation | 10-09-2010 |
References | PMC303291 |
PolysacDB ID | 1578 |
Carbohydrate Name | N-propionylated group B meningococcal polysaccharide (Drugpedia) |
Carbohydrate Class | Capsular polysaccharide |
Microbe | Neisseria meningitidis Serogroup B (NCBI Taxonomy) (Drugpedia) |
Basic Structure | It is a homopolymer of α(2-->8) sialic acid |
BCSDB Structure | N/A |
Proposed functions | This capsular polysaccharide is an important virulence determinant. Serum antibodies to the group B polysaccharide confers protection against disease by activating complement-mediated bacteriolysis and/or opsonization. It leads to immunologic tolerance induced by prenatal exposure to host polysialyated glycoproteins |
Antigenic Nature used to produce antibodies | Glycoconjugates |
Carrier Name | Tetanus toxoid |
Conjugation Method | Nil |
Antibodies | Polysera |
Antibody type and class | N/A |
Assay System | Radioactive binding inhibition assay, ELISA, Bactericidal assay |
Cross-reactivity | This antisera cross-reacted with capsular polysaccharide of E. coli K1 |
Proposed epitopes | N/A |
IEDB Epitope | N/A |
Proposed Utility | This antisera was bactericidal for Group B meningococci |
Curator ID | AA + AS |
Date of Curation | 12-09-2010 |
References | 2469720 |
PolysacDB ID | 1617 |
Carbohydrate Name | Lipooligosaccharide (Drugpedia) |
Carbohydrate Class | Lipopolysaccharide |
Microbe | Moraxella catarrhalis serotype A (NCBI Taxonomy) (Drugpedia) |
Basic Structure | LOS consists of an oligosaccharide and lipid A and is similar to the lipopolysaccharide (LPS) of gramnegative enteric pathogens, but it lacks the O-antigenic side chain of repeating units characteristic of classical LPS. The oligosaccharide part consists of the following residues : α-D-Galp-(1-->4)-β-D-Galp-(1-->4)-α-D-Glcp-(1-->2)-β-D-Glcp-(1-->6)-α-D-Glcp [branched to α-D-GlcpNAc-(1-->2)-β-D-Glcp-(1-->4)] and [branched to β-D-Glcp-(1-->3)] -(1-->5)-Kdo |
BCSDB Structure | 22728 |
Proposed functions | Moracella lipooligosaccharide is a potential virulence factor |
Antigenic Nature used to produce antibodies | Whole cells |
Carrier Name | Nil |
Conjugation Method | Nil |
Antibodies | Polysera |
Antibody type and class | N/A |
Assay System | ELISA and immunoblotting |
Cross-reactivity | This antisera was specific to serotype A |
Proposed epitopes | A terminal α-D-GlcNAc-(1-->2)-β-D-Glc seemed to be a part of the epitope |
IEDB Epitope | N/A |
Proposed Utility | This antisera may help in sertotyping of moraxella strains |
Curator ID | AA + AS |
Date of Curation | 23-09-2010 |
References | 8636949 |
PolysacDB ID | 1618 |
Carbohydrate Name | Lipooligosaccharide (Drugpedia) |
Carbohydrate Class | Lipopolysaccharide |
Microbe | Moraxella catarrhalis serotype B (NCBI Taxonomy) (Drugpedia) |
Basic Structure | LOS consists of an oligosaccharide and lipid A and is similar to the lipopolysaccharide (LPS) of gramnegative enteric pathogens, but it lacks the O-antigenic side chain of repeating units characteristic of classical LPS. The oligosaccharide part consists of the following residues : α-D-Galp-(1-->4)-β-D-Galp-(1-->4)-α-D-Glcp-(1-->2)-β-D-Glcp-(1-->4)-α-D-Glcp [branched to α-D-Galp-(1-->4)-&blpha;-D-Galp-(1-->4)-α-D-Glcp-(1-->2)-β-D-Glcp-(1-->6)] and [branched to β-D-Glcp-(1-->3)] -(1-->5)-Kdo |
BCSDB Structure | 21752 |
Proposed functions | Moracella lipooligosaccharide is a potential virulence factor |
Antigenic Nature used to produce antibodies | Whole cells |
Carrier Name | Nil |
Conjugation Method | Nil |
Antibodies | Polysera |
Antibody type and class | N/A |
Assay System | ELISA and immunoblotting |
Cross-reactivity | This antisera was specific to serotype B |
Proposed epitopes | A terminal β-D-Gal-(1-->4)-β-D-Glc seemed to be a part of the epitope |
IEDB Epitope | N/A |
Proposed Utility | This antisera may help in sertotyping of moraxella strains |
Curator ID | AA + AS |
Date of Curation | 24-09-2010 |
References | 8636949 |
PolysacDB ID | 1619 |
Carbohydrate Name | Lipooligosaccharide (Drugpedia) |
Carbohydrate Class | Lipopolysaccharide |
Microbe | Moraxella catarrhalis serotype C (NCBI Taxonomy) (Drugpedia) |
Basic Structure | LOS consists of an oligosaccharide and lipid A and is similar to the lipopolysaccharide (LPS) of gramnegative enteric pathogens, but it lacks the O-antigenic side chain of repeating units characteristic of classical LPS. The oligosaccharide part consists of the following residues : α-D-Galp-(1-->4)-β-D-Galp-(1-->4)-α-D-Glcp-(1-->2)-β-D-Glcp-(1-->6)-α-D-Glcp [branched to β-D-Galp-(1-->4)-α-D-GlcpNAc-(1-->2)-β-D-Glcp-(1-->4)] and [branched to β-D-Glcp-(1-->3)] -(1-->5)-α-Kdop [branched to Kdop-(2-->4)] |
BCSDB Structure | 22728 |
Proposed functions | Moracella lipooligosaccharide is a potential virulence factor |
Antigenic Nature used to produce antibodies | Whole cells |
Carrier Name | Nil |
Conjugation Method | Nil |
Antibodies | Polysera |
Antibody type and class | N/A |
Assay System | ELISA and immunoblotting |
Cross-reactivity | This antisera cross-reacted with Serotype A LPS |
Proposed epitopes | A terminal β-D-Gal-(1-->4)-α-D-GlcNA seemed to be a part of the epitope |
IEDB Epitope | N/A |
Proposed Utility | This antisera may help in sertotyping of moraxella strains |
Curator ID | AA + AS |
Date of Curation | 24-09-2010 |
References | 8636949 |
PolysacDB ID | 1620 |
Carbohydrate Name | Lipooligosaccharide (Drugpedia) |
Carbohydrate Class | Lipopolysaccharide |
Microbe | Moraxella catarrhalis B strain 26397 (NCBI Taxonomy) (Drugpedia) |
Basic Structure | LOS consists of an oligosaccharide and lipid A and is similar to the lipopolysaccharide (LPS) of gramnegative enteric pathogens, but it lacks the O-antigenic side chain of repeating units characteristic of classical LPS. The oligosaccharide part consists of the following residues : α-D-Galp-(1-->4)-β-D-Galp-(1-->4)-α-D-Glcp-(1-->2)-β-D-Glcp-(1-->4)-α-D-Glcp [branched to α-D-Galp-(1-->4)-&blpha;-D-Galp-(1-->4)-α-D-Glcp-(1-->2)-β-D-Glcp-(1-->6)] and [branched to β-D-Glcp-(1-->3)] -(1-->5)-Kdo |
BCSDB Structure | N/A |
Proposed functions | Moracella lipooligosaccharide is a potential virulence factor |
Antigenic Nature used to produce antibodies | Glycoconjugates |
Carrier Name | Tetanus toxoid |
Conjugation Method | Adipic acid dihydrazide [ADH] was introduced to the carboxyl group of Kdo moiety of the detoxified lipooligosaccharide [LOS] to form adipic hydrazide (AH)-dLOS derivatives, using 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide HCl (EDC) and N-hydroxysulfosuccinimid. dLOS (96 mg) was dissolved in 12 ml of 287 mM ADH (50 mg/ml, molar ratio of ADH to dLOS is 108 to 1 based on an estimated Mrof 3,000 for dLOS). AH-dLOS (45 mg) was dissolved with 4.5 ml of 0.2 M NaCl to make a 10 mg/ml solution of AH-dLOS. For the conjugation reaction, each 20 mg of AH-dLOS solution (2 ml in volume) was mixed with 10 mg of cross-reactive mutant (CRM) of diphtheria toxin (0.44 ml in volume). The initial concentration of AH-dLOS or CRM was 8.20 or 4.10 mg/ml. The molar ratio of AH-dLOS to CRM (Mr 67,000) was 45 to 1. The pH was adjusted to 5.0-5.2 with 0.1 M HCl, followed by addition of 0.05 M EDC. The reaction was maintained at pH 5.0 to 5.2 for 4 h at 4°C, then adjusted to pH 7.0, dialyzed against 0.9% NaCl for 2 to 3 days, centrifuged, and passed through a Sephacryl S-300 column (2.6 by 90 cm) in 0.9% NaCl. Peaks that contained both protein and carbohydrate were pooled and designated as dLOS-TT or dLOS-CRM. Both conjugates were analyzed for their composition of carbohydrate and protein using dLOS and bovine serum albumin (BSA) as standards |
Antibodies | Polysera |
Antibody type and class | N/A |
Assay System | ELISA, Bactericidal assay and immunoblotting |
Cross-reactivity | This antisera was specific to Serotype B and reacted with nine of twelve clinical isolates studied |
Proposed epitopes | N/A |
IEDB Epitope | N/A |
Proposed Utility | This antisera showed elevated complement-mediated bactericidal activity against the homologous strain |
Curator ID | AA + AS |
Date of Curation | 24-09-2010 |
References | PMC1087343 |
PolysacDB ID | 1621 |
Carbohydrate Name | Lipooligosaccharide (Drugpedia) |
Carbohydrate Class | Lipopolysaccharide |
Microbe | Moraxella catarrhalis Serotype A strain 25238 (NCBI Taxonomy) (Drugpedia) |
Basic Structure | LOS consists of an oligosaccharide and lipid A and is similar to the lipopolysaccharide (LPS) of gramnegative enteric pathogens, but it lacks the O-antigenic side chain of repeating units characteristic of classical LPS. The oligosaccharide part consists : α-D-Galp-(1-->4)-β-D-Galp-(1-->4)-α-D-Glcp-(1-->2)-β-D-Glcp-(1-->6)-α-D-Glcp [branched to α-D-GlcpNAc-(1-->2)-β-D-Glcp-(1-->4)] and [branched to β-D-Glcp-(1-->3)-(1-->5)-Kdo |
BCSDB Structure | N/A |
Proposed functions | Moracella lipooligosaccharide is a potential virulence factor |
Antigenic Nature used to produce antibodies | Glycoconjugates |
Carrier Name | Tetanus toxoid |
Conjugation Method | Adipic acid dihydrazide (ADH) was bound to detoxified lipooligosaccharide [LOS] to form adipic hydrazide (AH)-dLOS derivatives, using 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide HCl (EDC) and N-hydroxysulfosuccinimide (sulfo-NHS). dLOS (70 mg) was dissolved in 7 ml of 345 mM ADH (molar ratio of ADH to LOS is 100 to 1, based on an estimated Mr of 3,000 for dLOS). Sulfo-NHS was added to a concentration of 8 mM, the pH was adjusted to 4.8, and EDC was added to a concentration of 0.1 M. The reaction mixture was stirred and maintained at pH 4.8 for 3 h. The reaction mixture was adjusted to pH 7.0 and passed through the G-50 column as described above. The eluate was assayed for carbohydrate and for ADH. The peaks containing both carbohydrate and AH were pooled, freeze-dried, and designated AH-dLOS. AH-dLOS was measured for its composition, using dLOS and ADH as standards |
Antibodies | Polysera |
Antibody type and class | N/A |
Assay System | Double immunodiffusion |
Cross-reactivity | N/A |
Proposed epitopes | N/A |
IEDB Epitope | N/A |
Proposed Utility | This antisera had complementmediated bactericidal activity against the homologous strain and heterologous strains of M. catarrhalis |
Curator ID | AA + AS |
Date of Curation | 24-09-2010 |
References | 9573066 |
PolysacDB ID | 1622 |
Carbohydrate Name | Lipooligosaccharide (Drugpedia) |
Carbohydrate Class | Lipopolysaccharide |
Microbe | Moraxella catarrhalis serotype C strain 26404 (NCBI Taxonomy) (Drugpedia) |
Basic Structure | LOS consists of an oligosaccharide and lipid A and is similar to the lipopolysaccharide (LPS) of gramnegative enteric pathogens, but it lacks the O-antigenic side chain of repeating units characteristic of classical LPS. The oligosaccharide part consists of the following residues : α-D-Galp-(1-->4)-β-D-Galp-(1-->4)-α-D-Glcp-(1-->2)-β-D-Glcp-(1-->6)-α-D-Glcp [branched to β-D-Galp-(1-->4)-α-D-GlcpNAc-(1-->2)-β-D-Glcp-(1-->4)] and [branched to β-D-Glcp-(1-->3)] -(1-->5)-α-Kdop [branched to Kdop-(2-->4)] |
BCSDB Structure | N/A |
Proposed functions | Moracella lipooligosaccharide is a potential virulence factor |
Antigenic Nature used to produce antibodies | Glycoconjugates |
Carrier Name | Tetanus toxoid |
Conjugation Method | 240 mg of lipooligosaccharide [LOS] was detoxified by using anhydrous hydrazine, and the dLOS was purified. Then adipic acid dihydrazide was conjugated to the dLOS (96 mg) in 12 ml of a 287 mM adipic acid dihydrazide suspension to form adipic hydrazide (AH)-dLOS derivatives, using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide HCl and N-hydroxysulfosuccinimide. The resulting AH-dLOS was finally coupled to Tetanus toxoid [TT]. 10 mg of TT (Mr, 150,000) was reacted with 20 mg of AH-dLOS (10 mg/ml) at a molar ratio of AH-dLOS to TT of 100:1 using 0.05 M 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide HCl. All reaction mixtures were maintained at pH 5.0 to 5.2 for 4 h at 4°C, and the reactions were stopped by adjusting the pH to 7.0. The reaction mixtures were dialyzed against 0.9% NaCl for 2 to 3 days, centrifuged, and passed through a Sephacryl S-300 column (2.6 by 90 cm) in 0.9% NaCl. Peaks that contained both protein and carbohydrate were pooled and designated dLOS-TT, dLOS-CRM-1, and dLOS-CRM-2. The three conjugates were analyzed to determine their carbohydrate and protein contents using dLOS and bovine serum albumin as standards |
Antibodies | Polysera |
Antibody type and class | N/A |
Assay System | ELISA, Bactericidal assay and bactericidal inhibition assay |
Cross-reactivity | This antisera cross-reacted with Serotype A LPS and to a little extent to Serotype B |
Proposed epitopes | N/A |
IEDB Epitope | N/A |
Proposed Utility | This antisera showed complement-mediated bactericidal activity against the homologous strain |
Curator ID | AA + AS |
Date of Curation | 24-09-2010 |
References | PMC1932890 |
PolysacDB ID | 1623 |
Carbohydrate Name | Lipooligosaccharide (Drugpedia) |
Carbohydrate Class | Lipopolysaccharide |
Microbe | Moraxella catarrhalis Serotype A strain 25238 (NCBI Taxonomy) (Drugpedia) |
Basic Structure | LOS consists of an oligosaccharide and lipid A and is similar to the lipopolysaccharide (LPS) of gramnegative enteric pathogens, but it lacks the O-antigenic side chain of repeating units characteristic of classical LPS. The oligosaccharide part consists of the following residues : α-D-Galp-(1-->4)-β-D-Galp-(1-->4)-α-D-Glcp-(1-->2)-β-D-Glcp-(1-->6)-α-D-Glcp [branched to α-D-GlcpNAc-(1-->2)-β-D-Glcp-(1-->4)] and [branched to β-D-Glcp-(1-->3)] -(1-->5)-Kdo |
BCSDB Structure | N/A |
Proposed functions | Moracella lipooligosaccharide is a potential virulence factor |
Antigenic Nature used to produce antibodies | Glycoconjugates |
Carrier Name | Cross-reactive mutant (CRM9) of diphtheria toxin |
Conjugation Method | Adipic acid dihydrazide (ADH) was bound to detoxified lipooligosaccharide [LOS] to form adipic hydrazide (AH)-dLOS derivatives, using 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide HCl (EDC) and N-hydroxysulfosuccinimide (sulfo-NHS). dLOS (70 mg) was dissolved in 7 ml of 345 mM ADH (molar ratio of ADH to LOS is 100 to 1, based on an estimated Mr of 3,000 for dLOS). Sulfo-NHS was added to a concentration of 8 mM, the pH was adjusted to 4.8, and EDC was added to a concentration of 0.1 M. The reaction mixture was stirred and maintained at pH 4.8 for 3 h. The reaction mixture was adjusted to pH 7.0 and passed through the G-50 column as described above. The eluate was assayed for carbohydrate and for AH. The peaks containing both carbohydrate and AH were pooled, freeze-dried, and designated AH-dLOS. AH-dLOS was measured for its composition, using dLOS and ADH as standards |
Antibodies | Polysera |
Antibody type and class | N/A |
Assay System | Enzyme-linked immunospot assay, ELISA and Bacterial challenge assay |
Cross-reactivity | N/A |
Proposed epitopes | N/A |
IEDB Epitope | N/A |
Proposed Utility | The dLOS-CRM vaccine induced a significant bacterial clearance (70 to 90%) of both homologous and heterologous strains in the lungs compared to that observed in the controls |
Curator ID | AA + AS |
Date of Curation | 25-09-2010 |
References | PMC130355 |
PolysacDB ID | 1742 |
Carbohydrate Name | Phenolic glycolipid-I (Drugpedia) |
Carbohydrate Class | Glycolipid |
Microbe | Mycobacterium leprae (NCBI Taxonomy) (Drugpedia) |
Basic Structure | Phenolic glycolipid-1 is a M. leprae-specific antigen that contains a unique trisaccharide, 3,6-di-O-methyl-β-D-glucopyranosyl-(1-->4)-2,3-di-O-methyl-α-L-rhamnopyranosyl-(1-->2)-3-O-methyl-α-L-rhamnopyranose |
BCSDB Structure | N/A |
Proposed functions | It has been widely used for the serodiagnosis of leprosy and has been implicated in the pathogenesis of leprosy |
Antigenic Nature used to produce antibodies | Whole cells |
Carrier Name | Nil |
Conjugation Method | Nil |
Antibodies | Polysera |
Antibody type and class | IgM |
Assay System | ELISA |
Cross-reactivity | The antisera cross-reacted withserovars 5, 12, 18, 20, 23, 24, and 28 of M. avium-M. intracellulare-M. scrofulaceum serocomplex |
Proposed epitopes | The trisaccharide appendages of the phenolic glycolipids seemed to be a part of the epitope |
IEDB Epitope | 76905 |
Proposed Utility | A specific assay for IgM activity to the specific M. leprae glycolipid, particularly in the preclinical state of the lepromatous form of the disease, may enable earlier chemotherapy and thereby prevent deformity and eliminate the infectious reservoir |
Curator ID | AA + AS |
Date of Curation | 20-10-2010 |
References | PMC264610 |
PolysacDB ID | 1761 |
Carbohydrate Name | Peptide mimotope (Drugpedia) |
Carbohydrate Class | Glycoprotein |
Microbe | Mycobacterium tuberculosis (NCBI Taxonomy) (Drugpedia) |
Basic Structure | The peptide consisted of the following sequence : QEPLMGTVPIRAGGGS |
BCSDB Structure | N/A |
Proposed functions | N/A |
Antigenic Nature used to produce antibodies | Purified peptide |
Carrier Name | Nil |
Conjugation Method | Nil |
Antibodies | Polysera |
Antibody type and class | N/A |
Assay System | ELISA, immunoblotting |
Cross-reactivity | This antisera recognized mannosylated Mycobacterium tuberculosis cell-wall antigens arabinomannan, lipoarabinomannan and the glycosylated recombinant protein Apa. The antisera also cross-reacted with mannans from Saccharomyces cerevisiae, but did not react with phosphatidyl-inositol-di-mannoside or arabinogalactan from Mycobacteria |
Proposed epitopes | The epitope was proposed to be oligomannosidic in nature |
IEDB Epitope | N/A |
Proposed Utility | This peptide mimotope can used as surrogate reagent for immunodiagnosis of tuberculosis |
Curator ID | AA + AS |
Date of Curation | 24-10-2010 |
References | PMC1134969 |
PolysacDB ID | 1918 |
Carbohydrate Name | Capsular polysaccharide (Drugpedia) |
Carbohydrate Class | Capsular polysaccharide |
Microbe | Pneumococci spp. (NCBI Taxonomy) (Drugpedia) |
Basic Structure | The capsular polysaccharide of Pneumococcus sp. 14 consists of the following residues : -4)-β-D-Glcp-(1-->6)-β-D-GlcpNAc [branched to β-D-Galp-(1-->4)] -(1-->3)-β-D-Galp-(1- |
BCSDB Structure | 21255 |
Proposed functions | N/A |
Antigenic Nature used to produce antibodies | A vaccine preparation of type 6 (Danish type 6A) pneumococcal capsular polysaccharide |
Carrier Name | Nil |
Conjugation Method | Nil |
Antibodies | Polysera |
Antibody type and class | N/A |
Assay System | Hemolytic plaque assay |
Cross-reactivity | The antisera cross-reacted with S14, S19, or S23 capsular polysaccharides |
Proposed epitopes | The antisera was proposed to be directed against a immunodominant polysaccharide PnC |
IEDB Epitope | N/A |
Proposed Utility | N/A |
Curator ID | AA + AS |
Date of Curation | 28-11-2010 |
References | PMC260941 |
PolysacDB ID | 1919 |
Carbohydrate Name | Capsular polysaccharide (Drugpedia) |
Carbohydrate Class | Capsular polysaccharide |
Microbe | Pneumococci spp. (NCBI Taxonomy) (Drugpedia) |
Basic Structure | The capsular polysaccharide of Pneumococcus sp. 14 consists of the following residues : -4)-β-D-Glcp-(1-->6)-β-D-GlcpNAc [branched to β-D-Galp-(1-->4)] -(1-->3)-β-D-Galp-(1- |
BCSDB Structure | 21255 |
Proposed functions | N/A |
Antigenic Nature used to produce antibodies | A vaccine preparation of type 14 pneumococcal capsular polysaccharide |
Carrier Name | Nil |
Conjugation Method | Nil |
Antibodies | Polysera |
Antibody type and class | N/A |
Assay System | Hemolytic plaque assay |
Cross-reactivity | The antisera cross-reacted with S6, S19, or S23 capsular polysaccharides |
Proposed epitopes | The antisera was proposed to be directed against a immunodominant polysaccharide PnC |
IEDB Epitope | N/A |
Proposed Utility | N/A |
Curator ID | AA + AS |
Date of Curation | 29-11-2010 |
References | PMC260941 |
PolysacDB ID | 1920 |
Carbohydrate Name | Capsular polysaccharide (Drugpedia) |
Carbohydrate Class | Capsular polysaccharide |
Microbe | Pneumococci spp. (NCBI Taxonomy) (Drugpedia) |
Basic Structure | The capsular polysaccharide of Pneumococcus sp. 14 consists of the following residues : -4)-β-D-Glcp-(1-->6)-β-D-GlcpNAc [branched to β-D-Galp-(1-->4)] -(1-->3)-β-D-Galp-(1- |
BCSDB Structure | 21255 |
Proposed functions | N/A |
Antigenic Nature used to produce antibodies | A vaccine preparation of type 19 pneumococcal capsular polysaccharide |
Carrier Name | Nil |
Conjugation Method | Nil |
Antibodies | Polysera |
Antibody type and class | N/A |
Assay System | Hemolytic plaque assay |
Cross-reactivity | The antisera cross-reacted with S14, S6, or S23 capsular polysaccharides |
Proposed epitopes | The antisera was proposed to be directed against a immunodominant polysaccharide PnC |
IEDB Epitope | N/A |
Proposed Utility | N/A |
Curator ID | AA + AS |
Date of Curation | 29-11-2010 |
References | PMC260941 |
PolysacDB ID | 1921 |
Carbohydrate Name | Capsular polysaccharide (Drugpedia) |
Carbohydrate Class | Capsular polysaccharide |
Microbe | Pneumococci spp. (NCBI Taxonomy) (Drugpedia) |
Basic Structure | The capsular polysaccharide of Pneumococcus sp. 14 consists of the following residues : -4)-β-D-Glcp-(1-->6)-β-D-GlcpNAc [branched to β-D-Galp-(1-->4)] -(1-->3)-β-D-Galp-(1- |
BCSDB Structure | 21255 |
Proposed functions | N/A |
Antigenic Nature used to produce antibodies | A vaccine preparation of type 23 pneumococcal capsular polysaccharide |
Carrier Name | Nil |
Conjugation Method | Nil |
Antibodies | Polysera |
Antibody type and class | N/A |
Assay System | Hemolytic plaque assay |
Cross-reactivity | The antisera cross-reacted with S14, S19, or S6 capsular polysaccharides |
Proposed epitopes | The antisera was proposed to be directed against a immunodominant polysaccharide PnC |
IEDB Epitope | N/A |
Proposed Utility | N/A |
Curator ID | AA + AS |
Date of Curation | 29-11-2010 |
References | PMC260941 |
PolysacDB ID | 1970 |
Carbohydrate Name | 23-valent pneumococcal vaccine (Drugpedia) |
Carbohydrate Class | Capsular polysaccharide |
Microbe | Streptococcus pneumoniae (NCBI Taxonomy) (Drugpedia) |
Basic Structure | N/A |
BCSDB Structure | N/A |
Proposed functions | N/A |
Antigenic Nature used to produce antibodies | Commercial vaccine preparation |
Carrier Name | Nil |
Conjugation Method | Nil |
Antibodies | Polysera |
Antibody type and class | IgG |
Assay System | ELISA |
Cross-reactivity | This antisera was specific to pneumococcal polysaccharide and did not cross-react with Haemophilus influenzae type B capsular polysaccharide |
Proposed epitopes | N/A |
IEDB Epitope | N/A |
Proposed Utility | This antisera would promote research on the efficacy of the vaccine in risk groups and will permit in-depth studies of the immunological response in patients |
Curator ID | AA + AS |
Date of Curation | 08-12-2010 |
References | PMC170496 |
PolysacDB ID | 2642 |
Carbohydrate Name | Capsular polysaccharide (Drugpedia) |
Carbohydrate Class | Capsular polysaccharide |
Microbe | Cryptococcus neoformans Serotype D (NCBI Taxonomy) (Drugpedia) |
Basic Structure | This polysaccharide is a high m.w. polymer with a linear α-(1-->3)-linked mannose backbone that is substituted with non-reducing D-xyIosyal and D-glucosyluronic acid groups. O-Acetylation varies with the serotype. Type D is the most heavily O-acetylated |
BCSDB Structure | 136943 |
Proposed functions | Antiphagocytic ; an important virulence factor |
Antigenic Nature used to produce antibodies | Glycoconjugates |
Carrier Name | Methylated bovine serum albumin |
Conjugation Method | A saline solution containing 500 pg of cryptococcal polysaccharide was mixed with 500 pg aqueous methylated bovine serum albumin. The volume was brought to 2 ml with sterile distilled water |
Antibodies | Polysera |
Antibody type and class | IgG |
Assay System | Antiserum to untreated cryptococcal polysaccharide was enriched for O-acetyl and carboxyl specific antibody respectively. The antisera was then used in ouchterlony double diffusion. |
Cross-reactivity | N/A |
Proposed epitopes | N/A |
IEDB Epitope | N/A |
Proposed Utility | O-acetyl and carboxyl groups are strong and distinct physicochemical determinants on cryptococcal polysaccharide. The enriched antiserum displayed a level of opsonic activity that was similar to non-enriched antiserum. This showed that neither O-acetyl nor carboxyl groups were responsible for inhibition of phagocytosis by cryptococcal polysaccharide |
Curator ID | AA + AS |
Date of Curation | 30-07-2011 |
References | 15271943 |
Bioinformatics Centre, Institute of Microbial Technology, Sec - 39A, Chandigarh, India - 160036 |